About Calixa Therapeutics
Calixa Therapeutics is a Healthcare company based in San Mateo (United States) founded in 2007, and was acquired by Cubist Pharmaceuticals in December 2009. Development of a novel cephalosporin against the multi-drug resistant organisms. Calixa Therapeutics has raised $30.18 million across 1 funding round from investors including Cubist Pharmaceuticals, Frazier Healthcare Partners and Canaan. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Calixa Therapeutics, Inc. Its competitors include Paratek Pharma, Spero Therapeutics and Cempra; 3 of its 3 listed competitors have raised funding.
Company details
Calixa Therapeutics is focused on the development of a novel cephalosporin against the multi-drug resistant organisms. Its lead drug is a combination of two antibacterial compounds, cephalosporin and tazobactam antibiotics. Its cephalosporin compound (dubbed CXA-101) was acquired from Japanese drugmaker Astellas Pharma. Its lead product CXA-101 is an IV formulation of a novel cephalosporin that has shown potency, especially against multi-drug resistant Pseudomonas aeruginosa. It also had plans to combine this product with a beta-lactamase inhibitor; the combination product (CXA-201) has the potential to against the infections caused by gram-negative organisms. In June 2009, Cubist Pharmaceutical acquired Calyx Therapeutics for 402.5M. Cubist Pharmaceuticals was later acquired by Merck for 9.5B.
- Headquarters San Mateo, United States
- Stage Acquired
- SectorsHealthcare
- Website calixainc.com
- Acquired by Cubist Pharmaceuticals (Dec 2009)
- Legal Name Calixa Therapeutics, Inc
- Total Equity Funding$30.18M (USD)
in 1 rounds
- Latest Funding Round$30.18M (USD), Series A
Nov 2007
- InvestorsCubist Pharmaceuticals
& 3 more
- Acquired byCubist Pharmaceuticals
(Dec 2009)
Funding Insights of Calixa Therapeutics
Calixa Therapeutics has successfully raised a total of $30.18M through 1 strategic funding round. The most recent funding activity was a Series A round of $30.18 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.18M
- Total Rounds 1
- Last Round Series A — $30.18M
- First Round $30.18M
(Nov 2007)
- Investors Count 3
All 1 funding rounds of Calixa Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2007 | $30.18M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Calixa Therapeutics
Calixa Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals, Frazier Healthcare Partners and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Pharmaceuticals for acute care bacterial infections are developed and commercialized. | 1993 | cubist.com | Lexington, United States |
Investor details for Calixa Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Calixa Therapeutics
3 dated milestones of Calixa Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Calixa Therapeutics is founded.
- Funding First funding round of $30.2M.
- Exit Acquired by Cubist Pharmaceuticals.
Competitors of Calixa Therapeutics
Calixa Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Paratek Pharma, Spero Therapeutics and Cempra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials |
Detailed competitors of Calixa Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Calixa Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Calixa Therapeutics
Calixa Therapeutics was founded in 2007.
Calixa Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Calixa Therapeutics is a funded company, having raised a total of $30.18M across 1 funding round to date. The company's 1st funding round was a Series A of $30.18M, raised on Nov 2007.
Calixa Therapeutics is focused on the development of a novel cephalosporin against the multi-drug resistant organisms. Its lead drug is a combination of two antibacterial compounds, cephalosporin and tazobactam antibiotics. Its cephalosporin compound (dubbed CXA-101) was acquired from Japanese drugmaker Astellas Pharma. Its lead product CXA-101 is an IV formulation of a novel cephalosporin that has shown potency, especially against multi-drug resistant Pseudomonas aeruginosa. It also had plans to combine this product with a beta-lactamase inhibitor; the combination product (CXA-201) has the potential to against the infections caused by gram-negative organisms. In June 2009, Cubist Pharmaceutical acquired Calyx Therapeutics for 402.5M. Cubist Pharmaceuticals was later acquired by Merck for 9.5B.
Calixa Therapeutics's top competitors include Spero Therapeutics, Paratek Pharma and Cempra.
Calixa Therapeutics has 4 investors. Key investors include Cubist Pharmaceuticals, Frazier Healthcare Partners, Canaan, and Domain Associates.
Calixa Therapeutics operates through Calixa Therapeutics, Inc.
Yes. Calixa Therapeutics was acquired by Cubist Pharmaceuticals in December 2009.